PPAR-Mediated Bile Acid Glucuronidation: Therapeutic Targets for the Treatment of Cholestatic Liver Diseases
Open accessThe DOI matches its Crossref record; 83 of the 84 references it cites were found in a registry or an index.
Abstract
Cholestatic liver diseases, including primary biliary cholangitis (PBC) and primary sclerosing cholangitis (PSC), result from an impairment of bile flow that leads to the hepatic retention of bile acids, causing liver injury. Until recently, the only approved treatments for PBC were ursodeoxycholic acid (UDCA) and obeticholic acid (OCA). While these therapies slow the progression of PBC in the early stage of the disease, approximately 40% of patients respond incompletely to UDCA, and advanced cases do not respond. UDCA does not improve survival in patients with PSC, and patients often have dose-limiting pruritus reactions to OCA. Left untreated, these diseases can progress to fibrosis and cirrhosis, resulting in liver failure and the need for transplantation. These shortcomings emphasize the urgent need for alternative treatment strategies. Recently, nuclear hormone receptors have been explored as pharmacological targets for adjunct therapy because they regulate enzymes involved in bile acid metabolism and detoxification. In particular, the peroxisome proliferator-activated receptor (PPAR) has emerged as a therapeutic target for patients with PBC or PSC who experience an incomplete response to UDCA. PPARα is predominantly expressed in the liver, and it plays an essential role in the regulation of cytochrome P450 (CYP) and uridine 5’-diphospho-glucuronosyltransferase (UGT) enzymes, both of which are critical enzyme families involved in the regulation of bile acid metabolism and glucuronidation, respectively. Importantly, PPARα agonists, e.g., fenofibrate, have shown therapeutic benefits in reducing elevated markers of cholestasis in patients with PBC and PSC, and elafibranor, the first PPAR (dual α, β/δ) agonist, has been FDA-approved for the second-line treatment of PBC. Additionally, newer PPAR agonists that target various PPAR isoforms (β/δ, γ) are under development as an adjunct therapy for PBC or PSC, although their impact on glucuronidation pathways are less characterized. This review will focus on PPAR-mediated bile acid glucuronidation as a therapeutic pathway to improve outcomes for patients with PBC and PSC.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures

![Figure 2 Combination treatment with UDCA and fenofibrate alters the concentration and composition of -3/6 bile acid glucuronides during cholestatic liver diseases. Serum was collected from patients treated with either UDCA monotherapy (13–15 mg/kg/day)—“mono”—or combination treatment with UDCA and fenofibrate (145–160 mg/day)—“combo”. Serum bile acid glucuronide concentrations were measured using LC-MS/MS methodology. Data represent the total concentration of -3 and -6 bile acid glucuronides within each patient cohort [18]. PBC (n = 16 “mono”, n = 16 “combo”) and PSC (n = 11 “mono”, n = 12 “combo”). UDCA: ursodeoxycholic acid; PBC: primary biliary cholangitis; PSC: primary sclerosing cholangitis; LCA: lithocholic acid; DCA: deoxycholic acid; HCA: hyocholic acid; HDCA: hyodeoxycholic acid; CDCA: chenodeoxycholic acid.](https://figures.cochat.ai/paper-figures/a50280b894564336bf7395b4aa22c363/ppar-mediated-bile-acid-glucuronidation-therapeutic-targets-for-the-treatment-of-figure-2.jpg)
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Fibrates including, fenofibrate, gemfibrozil, and bezafibrate, act through activating peroxisome proliferator-activated receptor alpha (PPAR-α), a nuclear receptor involved in lipid metabolism and inflammation [33].”
From Second-Line Therapies in Primary Biliary Cholangitis: A Comparative Review of Obeticholic Acid, Fibrates, Seladelpar, and Elafibranor (2025) · cites this paper as [33]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“PPAR-α activation enhances bile acid metabolism and secretion [33,34].”
From Second-Line Therapies in Primary Biliary Cholangitis: A Comparative Review of Obeticholic Acid, Fibrates, Seladelpar, and Elafibranor (2025) · cites this paper as [33]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Peroxisome Proliferator-Activated Receptors: Nuclear Control of Metabolism*
Desvergne, B., & Wahli, W. (1999) · Endocrine Reviews · doi:10.1210/edrv.20.5.0380 · Cited by 3,086 · cited 1×
“PPAR is an important regulator of several genes involved in bile acid synthesis and metabolism [9].”
BackgroundKliewer, S. A., Umesono, K., Noonan, D. J., Heyman, R. A., & Evans, R. M. (1992) · Nature · doi:10.1038/358771a0 · Cited by 1,741 · cited 1×
“PPREs are characterized by direct repeats of AGGTCA spaced by one nucleotide [10].”
BackgroundA Placebo-Controlled Trial of Obeticholic Acid in Primary Biliary Cholangitis
Nevens, F., Andreone, P., Mazzella, G., Strasser, S. I., Bowlus, C., Invernizzi, P., Drenth, J. P. H., Pockros, P. J., Regula, J., Beuers, U., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1509840 · Cited by 1,131 · cited 1×
“Obeticholic acid (OCA) is also FDA-approved for the treatment of PBC; however, its anti-cholestatic effect is modest and pruritus is a limiting side effect [5].”
BackgroundBile acid signaling in metabolic disease and drug therapy
Li, T., & Chiang, J. Y. L. (2014) · Pharmacological Reviews · doi:10.1124/pr.113.008201 · Cited by 935 · cited 1×
“Furthermore, most bile acids in humans can also be conjugated to glycine and taurine, at a ~3:1 ratio [34].”
BackgroundA Placebo-Controlled Trial of Bezafibrate in Primary Biliary Cholangitis
Corpechot, C., Chazouillères, O., Rousseau, A., Le Gruyer, A., Habersetzer, F., Mathurin, P., Goria, O., Potier, P., Minello, A., Silvain, C., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1714519 · Cited by 642 · cited 2×
“Importantly, adjunct therapy with fibrates, e.g., fenofibrate and bezafibrate (pan-PPAR agonist; not FDA-approved), improves biochemical markers of cholestasis, including reducing elevated serum alkaline phosphatase (ALP) and reducing the toxicity of the bile acid pool in PBC and PSC [14–19].”
BackgroundIntestinal transport and metabolism of bile acids
Dawson, P. A., & Karpen, S. J. (2015) · Journal of Lipid Research · doi:10.1194/jlr.r054114 · Cited by 598 · cited 2×
“Evidence indicates that bile acid glucuronidation is an increasingly important and active process under cholestatic conditions [22,23].”
BackgroundA metabolic pathway for bile acid dehydroxylation by the gut microbiome
Funabashi, M., Grove, T. L., Wang, M., Varma, Y., McFadden, M. E., Brown, L. C., Guo, C., Higginbottom, S., Almo, S. C., & Fischbach, M. A. (2020) · Nature · doi:10.1038/s41586-020-2396-4 · Cited by 590 · cited 1×
“Next, CA and CDCA, produced in the liver, are converted to secondary bile acids, e.g., deoxycholic acid (DCA) and lithocholic acid (LCA), by bacterial 7 α -dehydroxylating enzymes present in the intestinal microflora [29].”
BackgroundGlobal chemical effects of the microbiome include new bile-acid conjugations
Quinn, R. A., Melnik, A. V., Vrbanac, A., Fu, T., Patras, K. A., Christy, M. P., Bodai, Z., Belda-Ferre, P., Tripathi, A., Chung, L. K., et al. (2020) · Nature · doi:10.1038/s41586-020-2047-9 · Cited by 579 · cited 1×
“Newer evidence indicates that organisms within the human microbiome can synthesize unique amino acid amide conjugates to CA, namely phenylalanine, tyrosine, or leucine, to produce microbially conjugated bile acids, including phenylalanocholic acid, tyrosocholic acid, and leucocholic acid [35].”
BackgroundUDP-glucuronosyltransferases and clinical drug-drug interactions
KIANG, T., ENSOM, M., & CHANG, T. (2005) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2004.10.013 · Cited by 552 · cited 1×
“In humans, hydrophobic molecules, e.g., bile acids, undergo glucuronidation catalyzed by UGT enzymes [38].”
BackgroundSher, T., Yi, H. F., McBride, O. W., & Gonzalez, F. J. (1993) · Biochemistry · doi:10.1021/bi00072a015 · Cited by 519
Cited by
Levy, C., Abouda, G. F., Bilir, B. M., Bonder, A., Bowlus, C. L., Campos‐Varela, I., Cazzagon, N., Chandok, N., Cheent, K. S., Cortez‐Pinto, H., et al. (2025) · Journal of Hepatology · doi:10.1016/j.jhep.2025.04.025 · Cited by 37
Trauner, M., Karpen, S. J., & Dawson, P. A. (2025) · Hepatology · doi:10.1097/hep.0000000000001438 · Cited by 32
“…BA synthesis (PPAR alpha and delta), increasing BA glucuronidation (PPAR alpha), and increasing canalicular BA and PL excretion (PPAR alpha), [230,231] PPAR agents ’ principal actions appear to be more anti-fibrotic and anti-inflammatory through non-parenchymal cells, properties known for many…”
Ghallab, A., Mandorfer, M., Stirnimann, G., Geyer, J., Lindström, E., Luedde, T., der Merwe, V., Rashidi‐Alavijeh, J., Schmidt, H., Karpen, S. J., et al. (2025) · Journal of Hepatology · doi:10.1016/j.jhep.2025.05.009 · Cited by 26
“28 Like the liver, 29 the kidney also possesses bile acid glucuronidation capacity 30 and may directly metabolise bile acids to promote their urinary excretion.”
Wang, X., Klaassen, C. D., Chen, X., & Zhang, Y. (2025) · Pharmacological Reviews · doi:10.1016/j.pharmr.2025.100073 · Cited by 18
Bashiri, K., Mattar, M. C., Meighani, A., & Mason, A. L. (2025) · Intestinal Research · doi:10.5217/ir.2025.00090 · Cited by 22
“Liver Diseases to CD The successful application of PPAR agonists in cholestatic liver diseases provides a compelling rationale for exploring their use in CD.”
Influential
Metadata
- Authors
- Gallucci, G. M., Hayes, C. M., Boyer, J. L., Barbier, O., Assis, D. N., & Ghonem, N. S.
- Affiliations
- University of Rhode Island (US)
- Yale University (US)
- Université Laval (CA)
- Corresponding author
- Ghonem, Nisanne S.
- Venue
- Cells
- Publisher
- MDPI AG
- Published
- 2024-08-01
- Volume
- 13
- Issue
- 15
- Pages
- 1296
- ISSN
- 2073-4409 (ISSN-L)
- PMC
- PMC11312002
- OpenAlex
- W4401218243
- Cited by
- 40
- References
- 84
- Citations by year
- 2026: 17 · 2025: 22 · 2024: 1
- FWCI
- 2.88
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Cells (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Topics
- Health Sciences › Medicine › Hepatology › Liver Diseases and Immunity
- Health Sciences › Medicine › Oncology › Drug Transport and Resistance Mechanisms
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Peroxisome Proliferator-Activated Receptors
- Keywords
- peroxisome proliferator-activated receptors, cholestatic liver disease, primary biliary cirrhosis, primary sclerosing cholangitis, PPARα agonist, fenofibrate, elafibranor, ursodeoxycholic acid, obeticholic acid, UGT enzymes, CYP enzymes, bile acid metabolism, nuclear receptors, adjunctive therapy
- MeSH terms
- Animals, Bile Acids and Salts, Cholestasis, Humans, Liver Cirrhosis, Biliary, Cholangitis, Sclerosing, Peroxisome Proliferator-Activated Receptors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: PPAR-Mediated Bile Acid Glucuronidation: Therapeutic Targets for the Treatment of Cholestatic Liver Diseases. https://app.cochat.ai/papers/10.3390/cells13151296
- The paper
- Gallucci, G. M., Hayes, C. M., Boyer, J. L., Barbier, O., Assis, D. N., & Ghonem, N. S. (2024). PPAR-Mediated Bile Acid Glucuronidation: Therapeutic Targets for the Treatment of Cholestatic Liver Diseases. Cells. https://doi.org/10.3390/cells13151296
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.